| SESSION HIGHLIGHTS | |||
|---|---|---|---|
| Time in Hrs (IST) | Track Code | Topics and Session Tracks | |
| 10:00 - 11:40 | Scientific Session | Track: Metastatic Breast Cancer | |
| 14:20 - 15:40 | Scientific Session | Track: Local - Locally Advanced Breast Cancer | |
| 16:30 - 18:15 | Scientific Session | Track: Head & Neck Cancers | |
| 19:00 - 20:30 | HCG | Dinner Symposium | |
| Session 01 | Metastatic Breast Cancer | Grand Ball Room | |||
|---|---|---|---|
| Chairperson: Dr. Shekar Patil (MO), Dr. Hamanth Malhotra (MO) | |||
| Time in Hrs (IST) | Track Code | Paper ID | Topic |
| 10:00 – 10:20 | Industry (20 Mins) |
Welcome Address |
|
| 10:20 - 10:40 | Industry (20 Mins) |
Industry Session by Astra Zeneca: Topic: Endocrine resistance in HR+ve mBC in era of precision medicine Dr. Srinivas K G (MO) |
|
| 10:40 - 10:55 | Invited (15 Mins) |
Invited Talk: Topic: Are we there yet? Molecular monitoring in HR Positive mBC Dr. Niti Raizada (MO) |
|
| 10:55 - 11:15 | MBC (06 Mins) |
1013 | Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s
choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor positive (HR+) metastatic breast cancer (mBC) in DESTINYBreast06 (DB-06). Dr. Prashanth Kumar Parida (MO) |
| MBC (06 Mins) |
LBA1008 | Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP)
for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic
breast cancer (a/mBC): Primary results from DESTINY-Breast09.
Dr. Akansha Choudhary (MO) |
|
| MBC (06 Mins) |
LBA109 | Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in
patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the
randomized phase 3 ASCENT-04/KEYNOTE-D19 study.
Dr. Bhavesh Poladia (MO) |
|
| Moderators: Dr Jyoti Bajpai (MO) | |||
| 11:15 - 11:35 | Panel (20 Mins) |
Panel Discussion: Breast Cancer - Metastatic
Dr. Nishita Shetty (MO), Dr. Prashant Kumar Parida (MO), Dr. Vishwajit Pai (MO) Dr. Sarah Easaw (MO), Dr. Nidhi Tandon (MO) |
|
| 11:35 - 11:50 | Invited (20 Mins) |
Invited Talk: Topic: Topic Metastatic triple negative breast cancer beyond chemotherapy Dr. Biswajeet Dubashi (MO) |
|
| 11:50 - 12:10 | Industry (20 Mins) |
Industry Session by Astra Zeneca: Topic: ENHERTU® for the treatment of HR+ HER2-low or HR+ HER2 ultra-low mBC Dr. Vishwanath Sathyanarayanan (MO) |
|
| 12:10 - 12:30 | Industry (20 Mins) |
Industry Session by MSD: Topic: Redefining Treatment Outcomes with Immunotheraphy - Early Triple Negative Breast Cancer (TNBC) Dr. Niti Raizada (MO) |
|
| 12:30 - 13:00 | Keynote (30 Mins) |
Keynote Talk:: Topic: Harnessing the potential of modern participle beam therapy in immunomodulation and precision medicine to improve cancer survivals and survivorship Dr. Rakesh Jalali (RO) |
|
| 13:00 - 13:30 | Keynote (30 Mins) |
Keynote Talk: Topic: The Enigma of cancer:"Chasing Data driven outcomes, not protocols" Dr. BS Ajaikumar (RO) |
|
| 13:30 - 14:00 | (30 MINS) | Lunch Break | |
| 14:00 - 14:20 | Industry (20 Mins) |
Industry Session by Novartis: Topic: Panel Discussion on Patient Management considerations in HR+ HER2-Early Breast Cancer Dr. Amit Rauthan (MO) |
|
| Session 02 | Local - Locally Advanced Breast Cancer | |||
| Chairperson: : Dr. Gopinath K S (SO) | |||
| 14:20 - 14:30 | Invited (10 Mins) |
Invited Talk: Topic: Role of anti her2 treatment in locally advanced breast cancer Dr. Suresh Babu (MO) |
|
| 14:30 - 14:45 | Invited (15 Mins) |
Invited Talk: Topic: State of play: Neoadjuvant systemic therapy in Breast cancer Dr. Sachin Trivedi |
|
| 14:45 - 15:20 | LABC (07 Mins) |
LBA509 |
NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphide followed by weekly paclitaxel with or
without carboplatin for node-positive or high-risk node-negative TNBC.
Dr. Vinu Sarathy (MO) |
| LABC (07 Mins) |
501 |
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast
cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
Dr. Spoorthi (MO) |
|
| LABC (07 Mins) |
504 |
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
Dr. Aditya Sarin (MO) |
|
| LABC (07 Mins) |
505 |
15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the
SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or toxifen (T)+OFS.
Dr. Kiran P K (MO) |
|
| LABC (07 Mins) |
521 |
The effect of endocrine therapy omission on survival in ER-negative PR-low (1–10%) early-stage breast cancer treated with chemotherapy.
Dr. Santhosh Kumar KN (MO) |
|
| Moderators: Dr. Anitha Ramesh (MO) | |||
| 15:20 - 15:40 | Panel (20 Mins) |
Panel Discussion:Local - Locally Advanced Breast Cancer
Dr. Krithika Murugan (SO, Dr. Bhavya Bayana (SO), Dr. Janaki MG (RO), Dr. Kakoli Lahkar (MO), Dr. Harish P (MO), Dr. Rachan Shetty (MO) Dr. Ravi Chander Veligeti (SO), Dr. Sourabh Radhakrishnan (MO) |
|
| 15:40 - 16:00 | Industry (20 Mins) |
Industry Session by Lilly: Topic: Do all node postiive HR+ Her2+ early breast cancer patients have same risk of recurrence? Dr. Sai Vivek (MO) |
|
| 16:00 - 16:20 | Industry (20 Mins) |
Industry Session by Roche: Topic: Continuum of care in Her2 positive breast cancer Chairperson: Dr Govind Babu (MO) Moderator: Dr Avinash C B (MO) Panelists: Dr. Kiran PK (MO), Dr. Niti Raizada (MO), Dr. Satheesh CT (MO), Dr Sai Vivek (MO), Dr. Nidhi Tondon (MO), Dr. Vijai Simha (MO) |
|
| 16:20 - 16:25 | (05 MINS) | Tea Break | |
| Session 03 | | Track: Head & Neck Cancers | |||
| Chairperson: Dr. Purushottam Chawan (SO), Dr. Ramesh Bilimagge (RO) | |||
| 16:25 - 16:40 | Invited (15 Mins) |
Invite Talk: Topics: Indian T4b Buccal Cancers. Realigning staging and management Dr. Kaustubh Patel (SO) |
|
| 16:40 - 17:15 | HN (07 Mins) |
LBA2 |
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with
resected head and neck squous cell carcinoma at high risk of relapse.
Dr. Vijai Simha (MO) |
| HN 07 Mins) |
2509 |
Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and
beyond setting (DELII: Develoent of Low dose Immunotherapy in India).
Dr. Sandip Ganguly (MO) |
|
| HN (07 Mins) |
6001 |
Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squous cell carcinoma (CSCC).
Dr. Prathyush (MO) |
|
| HN (07 Mins) |
6008 |
Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic
thyroid cancer (BRAFm-ATC): A multicenter phase 2 trial.
Dr. Srigopal Mohanty (MO) |
|
| HN (07 Mins) |
6012 |
Neoadjuvant and adjuvant pembrolizumab plus standard of
care (SOC) in resectable locally advanced head and neck
squamous cell carcinoma (LA HNSCC): Exploratory efficacy
analyses of the phase 3 KEYNOTE-689 study.
Dr. Sneha Komineni (MO) |
|
| Chairperson: Dr. Dipak Haldipur (SO) | |||
| 17:15 - 17:45 | Keynote (30 Mins) |
Keynote Talk: Topics: Role of Immuno fluorescence in Surgical Oncology Dr. Raj Nagarkar (SO) |
|
| Moderators: Dr Neelesh Reddy (MO) | |||
| 17:45 - 18:05 | Panel (20 Mins) |
Panel Discussion: Head & Neck Cancers
Dr. Kinjal S Majumdar (SO), Dr. Sapna Nangia (RO), Dr. Prashant Nayak (RO) Dr. Sreevalli Anantharamu (MO), Dr. Prasad Eswaran (MO), Dr. Vivek Agarwala (MO) Dr. Chandrashekhar Prasad Singh (MO), Dr. Vaishnavi Joshi (MO) |
|
| 18:05 - 18:25 | Industry (20 Mins) |
Industry Session by MSD: Topics: Head and Neck Cancer awareness and role of Keytruda in treatment of M/uR HNSCC Patients Dr. Sanchayan Mandal (MO) |
|
| 18:25 - 18:45 | Industry (20 Mins) |
Industry Session by Astra Zeneca: Topics: Paradigm shift in the management of HER2 positive solid tumours Dr. Aditya Murali (MO) |
|
| 18:45 - 19:00 | (15 Mins) | Network Break | |
| Dinner Symposium | HealthCare Global Enterprises | Grand Ball Room | |||
| Chairperson: Dr. Ramesh Nimmagadda (RO) | |||
| 19:00 - 19:15 | Invited (15 Mins) |
AI in oncology : The Future is here
Ms. Shobha Vijayaraghavan, Accenture Panelists: Mr. Ravi Bharadhwaj |
|
| 19:15 - 19:45 | Keynote (30 Mins) |
Keynote Talk: Topics: Decoding the enigma of Cancer: A Multidisciplinary approach to precision oncology for better Patient outcomes Dr. BS Ajaikumar |
|
| 19:45 - 20:30 | Panel (45 Mins) |
Panel Presentation / Discussions / Q & A
Dr. Mithua Ghosh (Gen), Dr. Shantanu Chowdhury (Gen), Dr. Rahul Ramekar (Gen) Dr. Veena Ramaswamy (Path), Dr. Kumaraswamy (RO), Dr. Priyank Tripathi (CP) Dr. Abhishek Mohanty (Biorep), Dr. Shalini Thakur (SO) |
|
| Sessions Highlights - Hall - 4A (JUPITER) | |||
|---|---|---|---|
| Time in Hrs | Track Code | Topic and sessions Tracks | |
| 08:30 - 12:30 | Focus Session 1 | Palliative Oncology | |
| 14:00 - 17:00 | Scientific Session | Track: Hematologic Malignancies | |
| Session 04 | Track: Hematological Malignancies | |||
| Chairperson: Dr. Krishna Kumar Ratnam | |||
| Time in Hrs | Track Code | Paper Id | Topic and sessions Tracks |
| 13:30 - 14:00 | Invited 30 MINS |
Invited Talk: Topic: Establishing Industry collaboration with CAR-T Dr. Sharad Damodar |
|
| 14:00 - 14:20 | Invited 20 MINS |
Invited Talk: Topic: Relapsed Myeloma: Sequencing of Therapies Dr. Mallikarjun Kalashetty |
|
| 14:20 - 14:40 | Invited 20 MINS |
Invited Talk: Topic: Management of AML in the era of Targeted therapies Dr. Mahesh Rajashekhariah |
|
| 14:40 - 15:00 | Invited 20 MINS |
Invited Talk: Topic: Hematopathology Dr. Jayashree |
|
| 15:00 - 15:45 | HM 07 MINS |
LBA3 |
Results From VERIFY, a Phase 3, Double-Blind, Placebo(PBO)-Controlled Study of Rusfertide for
Treatment of Polycythemia Vera (PV).
Dr. Vikram Mathew |
| HM 07 MINS |
6504 |
An all-oral regimen of decitabine-cedazuridine (DEC-C) plus
venetoclax (VEN) in patients (pts) with newly diagnosed acute
myeloid leukemia (AML) ineligible for intensive induction
chemotherapy: Results from a phase 2 cohort of 101 pts.
Dr. Megala | |
| HM 07 MINS |
7000 |
Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.
Dr. Amreesh Sukumara | |
| HM 07 MINS |
7011 |
SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib
monotherapy in patients with del(17p) and treatment-naive
chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL)
Dr. Santhosh H S | |
| HM 07 MINS |
7015 |
Glofitab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell
lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO
Dr. Chaitanya Harita |
|
| HM 07 MINS |
7507 |
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1
patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Dr. P K Jayachandran | |
| 15:45 - 16:15 | Industry (30 Mins) |
Industry Session by ImmunoAct: Topic: The Role of NexCAR19 CAR T Cell Therapy in B-Cell Malignancies:From India to the World Dr. Vishwanath Sathyanarayanan (MO) |
|
| 16:15 - 16:45 | Industry (30 Mins) |
Industry Session by Takeda: Topic: Case based panel discussion in Hodgkin's Lymphoma Moderator: Dr. Amit Rauthan Panellists:Dr. Arun Warrior, Dr. Mangesh Kamath, Dr. K.G. Srinivas,Dr. Smitha Saldanha, Dr. Rajeev Vijay Kumar |
|
| 16:45 - 17:05 | Industry (20 Mins) |
Industry Session by Bard / BD: Topic: Revolutionising PICC placement: What lies in the future Dr. Hari Menon (MO) |
|
| 17:05 - 17:25 | Industry (20 Mins) |
Industry Session by Pfizer: Topic: Redefining the First-Line Management of ALK Rearranged NSCLC Dr. Prasad Narayanan (MO) |
|
| Moderators: Dr. Ashish Dixit | |||
| 17:25 - 17:55 | Panel (30 Mins) |
Panel Discussion:Hematological Malignancies
Dr. Revanth Boddu, Dr. Neema Bhat, Dr. Hari Menon, Dr. Mangesh Kamath Dr. S K Gupta, Dr. P K Jayachandran, Dr. Vimal Kumar G |
|
| Parallel Tracks | |||
| Focus Session 1 | Track: Onco Palliative Care | Hall 4A | |||
| Time in Hrs | Keynote Session | Topic | |
| 08:30 - 09:00 | Dr. Anuja Pandit | Digital Health and AI in Palliative Decision Support | |
| 09:00 - 09:30 | Dr. Nandini Vallath | Beyond Pain: Defining, Measuring, and Managing the Multidimensional Landscape of Serious Health-Related Suffering | |
| 09:30 - 10:00 | Ms. Smriti Rana | Rewriting the Narrative: Dignity, Identity, and Meaning in Cancer Care | |
| 10:00 - 10:15 | Tea Break | ||
| Panel Discussio | Topic | ||
| 10:15 - 11:25 |
Moderator: Dr. Praneeth Suvvari
Panelist:Dr. Vijay Agarwal, Dr. Amelia Michael, Prof. (Dr.) S.V. Joga Rao, Ms. Michelle Normen |
“They Want Everything Done” Navigating Demanding Families and Futile Intervention | |
| Time in Hrs | Keynote Session | Topic | |
| 11:25 - 11:55 | Dr. Raghavendra Ramanjulu | Patient-Reported Outcomes (PROs): From Clinical Trials to Clinical Care. | |
| 11:55 - 12:25 | Dr. Veereswara Raju SK | De-escalation of Cancer Therapy: A Palliative Opportunity | |
| Sessions Highlights - Hall - 4B (JUPITER) | ||||
|---|---|---|---|---|
| Time in Hrs | Track Code | Topics and Session Tracks | ||
| 10:00 - 12:30 | Focus Session 2 | Speech & Swallow | ||
| 13:30 - 17:40 | Focus Session 3 | Onco Pharma; Genomics & Precision Oncology | ||
| PRE CONFERENCE WORKSHOP | HALL 4B | ||||
| 08:00 - 10:00 | PCWS 120 MINS |
Postgraduate Exam Bootcamp: Skills, Strategy & Success - Medical Oncology
Examiners: Dr. Krishna Kumar Ratnam (MO), Dr. Suresh Babu (MO) |
||
| Focus Session 3 | Clinical Pharmacogenomics & Precision Oncology | ||||
| Time in Hrs | Topics | Speakers | ||
| 13:30 - 13:45 | Introductory address and workshop overview | Dr. Mithua Ghosh (Gen), Dr. Jyoti Bajpai (MO) | ||
| 13:45 - 14:05 | NGS Fundamental: Basics of NGS. What, Why and How? | Dr. Rahul Ramekar (Gen) | ||
| 14:05 - 14:25 | Data analyses: Overview of Tools and Databases; Data analysis workflow | Dr. Anuja Mishra | ||
| 14:25 - 14:45 | Overview of variant prioritization and interpretation in solid tumors | Dr Soundararajan Nagaraj | ||
| 14:45 - 15:05 | Precision Oncology: Where are we? | Dr. Om Shree Shetty (Gen) | ||
| 15:05 - 15:25 |
Industry Session by MGI Tech Co. Ltd: Topic: Enrichment Methods for Precision Oncology: NGS-based Hybrid Capture of CGP & Medium Pan-Cancer Amplicon Panels for Oncology ROI |
Dr. Ravi Kumar Chilukoti | ||
| 15:25 - 15:30 | Tea Break | |||
| 15:30 - 15:55 | Pharmacogenomics & Drug Targeting: Basics of Pharmacogenomics and its role in precision medicine: From Bench to bedside. | Dr. Priyank Tripathi (CP) | ||
| 15:55 - 16:15 | Pharmacogenomics: Future Perspective: Pharmacogenomics shaping drug development | Dr. Haritha P V (CP) | ||
| 16:15 - 16:35 |
Industry Session by Johnson & Johnson: Topic: A Breakthrough in NSCLC: The promise of Amivantamab for EGFR Exon 20 insertions |
Dr. Vishwajit Pai (MO) | ||
| 16:35 - 16:55 | Power of Genomic Medicine: Breast Cancer Genomics to India-specific Clinical Panels | Dr. Shantanu Chowdhury (Gen) | ||
| 16:55 - 17:15 |
Moderator: Dr Mithua Ghosh Topic: Case Studies in Precision Medicine. Patient case Discussion; genomic-guided oncology treatment |
Panelists: Dr. Vijay Aggarwal (MO), Dr. Srinivas BJ (MO) Dr. Jyoti Bajpai (MO), Dr. Amit Dutt (MO) Dr. Chandru J (Gen), Dr. Gautam Balram (Gen) Dr. Birendranath Banerjee (Gen) | ||
| 17:15 - 17:30 | Future Frontiers in Oncology: Advancing cancer care through integration of genomics, therapeutics, and innovation | Dr. BS Ajaikumar (RO) | ||
| 17:30 - 17:35 | Closing Remarks & Launch of the new educational program | Dr. Priyank Tripathi (CP), Dr. Rahul Ramekar (Gen) | ||
| Session Highlights - Hall - 5 (NEPTUNE) | ||||
|---|---|---|---|---|
| Time in Hrs | Track Code | Topics and Session Tracks | ||
| 08:30 - 17:30 | Focus Session 4 | Onco-Pathology | ||
| Focus Session 4 | Onco Pathology | ||||
| 08:30 - 09:15 | Registration | |||
| 09:15 - 09:20 | Inauguration | |||
| 09:20 - 09:25 | Context Setting - Dr. Veena Ramaswamy | |||
| SESSION - 01 BREAST BIOMARKERS | ||||
| Time in Hrs | Session | Speaker | ||
| 09:25 - 09:50 | Breast Biomarkers | Dr. Swarna Shivkumar | ||
| 09:50 - 10:05 | Latest Update in Her-2 interpretation | Dr. Manjit Kaur | ||
| 10:05 - 10:25 | Hands on Interpretation | |||
| 10:25 - 10:45 | Discussion | Moderated by: : Dr. Shaila B | ||
| 10:45 - 10:55 | Tea Break | |||
| SESSION - 02 IMMUNE CHECK POINT INHIBITORS | ||||
| 10:55 - 11:15 | Interpretation and application of PDL1 | Dr. Shilpa Prabhudesai | ||
| 11:15 - 11:35 | Hands on Interpretation | |||
| 11:35 - 11:50 | Discussion | |||
| 11:50 - 12:10 |
Industry Session by BMS: Topic: NSCLC topic: Breaking frontiers in 1L mNSCLC Leveraging Anti PD-1 & Anti CTLA-4 forhigh unmet need patients Dr. Mangesh Kamath (MO) |
|||
| 12:30 - 13:30 | Keynote Addess - Grand Ball Room | |||
| 13:10 - 13:40 | Lunch Break | |||
| 13:40 - 14:00 |
Industry Session by NATCO: TopicRole of TUCATINIB in HER 2 positive MBC Dr. Sai Vivek (MO) |
|||
| SESSION - 03 SURROGATE MARKERS OF IMMUNOTHERAPY | ||||
| 14:00 - 14:15 | MMR / MSI | Dr. Champaka | ||
| 14:15 - 14:30 | TMB | Dr. Gautam Balaram | ||
| 14:30 - 14:45 | Hands on Interpretation | |||
| 14:45 - 15:00 | Discussion | Moderated by: Dr. Champaka & Dr. Gautham B | ||
| SESSION - 04 LUNG BIOMARKERS | ||||
| 15:00 - 15:10 | Interpretation and Application of Lung Biomarkers | Dr. Tejaswini BN | ||
| 15:10 - 15:25 | Hands on Interpretation | |||
| 15:25 - 15:40 | Discussion | Moderated by: Dr. Tejaswini BN | ||
| 15:40 - 16:00 | Industry Session by Roche(Diagnostics): Biomarkers in early NSCLC - Focus on ALK | Dr. Veena Ramaswamy | ||
| 16:00 - 16:10 | Tea Break | |||
| SESSION - 05 OTHER TARGETED BIOMARKERS | ||||
| 16:10 - 16:30 | Other Targeted Biomarkers | Dr. Manjubala | ||
| 16:30 - 16:50 | Hands on Interpretation | |||
| 16:50 - 17:05 | Discussion | Moderated by: Dr. Manjubala | ||
| 17:05 - 17:15 | Active Interaction and Discussion | Dr. Kavita B | ||
| 17:15 - 17:20 | Vote of Thanks | |||
| Session Highlights - Hall(PLUTO) | ||||
|---|---|---|---|---|
| Time in Hrs | Track Code | Topics and Session Tracks | ||
| 10:00 - 11:20 | BoA Award Paper | Award Paper Presentation - Best of ASCO, Bengaluru | ||
| Pre Conference Workshop | HALL - 6 | ||||
| 08:00 - 10:00 | PCWS (120 Mins) |
Postgraduate Exam Bootcamp: Skills, Strategy & Success - Medical Oncology Examiners: Prof. Nirmala S (RO), Dr. Siddanna (RO) |
||
| Award Paper Session | Hall 6 | ||||
| Time in Hrs | Topic | Speakers | ||
| 10:00 - 10:07 | Residual cancer burden index (RCBI) after neoadjuvant therapy - an independent prognostic marker in carcinoma breast. | Dr. Garapati Divyajyothi | ||
| 10:07 - 10:14 | Survival outcome in node positive oral tongue cancer patients | Dr. Akhil P | ||
| 10:14 - 10:21 | Feasibility and clinical outcomes of the infrahyoid flap in reconstruction of small to medium-sized defects in oral cavity cancers | Dr. Sowmya T | ||
| 10:21 - 10:28 | Her2 expression detected by next-generation sequencing in a her2-negative males with secretory breast cancer: a precision-based diagnostic approach in a rare pediatric case | Dr. Somrita Das | ||
| 10:28 - 10:35 | To study the utility of Traffic Light Protocol (TLP) in head and neck VMAT | Dr. Rajalakshmi Radhakrishnan | ||
| 10:35 - 10:42 | Real-world treatment outcomes in malignant ovarian germ cell tumors: a single-center perspective | Dr. Snigdha Das | ||
| 10:42 - 10:49 | Surgical modalities of oral submucous fibrosis review of literature and a case view | Dr. Aniket Chauhan | ||
| 10:49 - 10:56 | Therapeutic outcomes of neo adjuvant immunotherapy in advanced hepatocellular carcinoma: a promising approach for curative intent | Dr. Manoj Kumar YL | ||
| 10:56 - 11:03 | Robotic vs laparoscopic adrenalectomy for pheochromocytoma - is there any difference? - a comparative study from a tertiary care cancer center. | Dr. Anirudh M | ||
| 11:03 - 11:10 | Immune-check point inhibitors related myocarditis: diagnostic dilemmas and emerging therapies | Dr. Maazen Naduthra Subair | ||
| Session Highlights - BOARD ROOM (Hall - 7) | |||
|---|---|---|---|
| Time in Hrs | Track Code | Topics and Session Tracks | |
| 14:00 - 17:30 | Focus Track | Radiation Oncology | |
| Session 5 | Track: Radiation Oncology Focus Track Hall - 7 | |||
| Chairperson: Dr. Lokesh Vishwanath (RO), Dr. Vijay Bhaskar (RO) | |||
| Time in Hrs | Track Code | Topics and Session Tracks | |
| 08:00 - 10:00 | PCWS (120 Mins) |
Postgraduate Exam Bootcamp: Skills, Strategy & Success - Medical Oncology Examiners: Prof. Chandramohan K (SO), Dr. Rakesh Ramesh (SO) |
|
| 14:00 - 14:20 | Invited (20 Mins) |
Invited Talk: Topic: Flash Radiotherapy: Is there light at the end of the tunnel Mr. Jerin (Physics) |
|
| 14:20 - 14:40 | Invited (20 Mins) |
Invited Talk: Topic: De escalation of Adjuvant RT in breast cancer - recent evidences Dr. Nirmala S (RO) |
|
| 14:40 - 15:10 | RO (07 Mins) |
LBA5504 |
Pembrolizumab with chemoradiotherapy in patients with
high-risk locally advanced cervical cancer: Final analysis results
of the phase 3, randomized, double-blind
ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Dr. Priya Sinha (SRO) |
| RO (07 Mins) |
LBA6003 |
PD-1 blockade with toripalimab incorporated into induction
chemotherapy and radiotherapy with or without concurrent
cisplatin in locoregionally advanced nasopharyngeal carcinoma
(DIAMOND): A multicenter, non-inferiority, phase 3, randomized
controlled trial.
Dr. Abhijit Sarkar (RO) |
|
| RO (07 Mins) |
6013 |
Long-term results of the randomized, phase 3 KEYNOTE-412 trial
of pembrolizumab (pembro) or placebo (pbo) plus concurrent
chemoradiotherapy (CRT) for unresected, locally advanced head
and neck squamous cell carcinoma (LA HNSCC).
Dr. Sunil (RO) |
|
| RO (07 Mins) |
LBA4005 |
PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with
gemcitabine and nab-paclitaxel for locally advanced pancreatic
ductal adenocarcinoma (LA-PAC).
Dr. Sindhu KR (RO) |
|
| Moderator: Dr. Geeta S Narayanan (RO) | |||
| 15:10 - 15:40 | Panel (30 Mins) |
Panel Discussion: Lung & Thoracic Cancers
Dr. Vinay Ural (RO), Dr. Mohan (RO), Dr. Kirthi Koushik (RO), Dr. Afthab Ansari (RO), Dr. Vinaykumar Muttagi (RO), Dr. Tanvir Pasha (RO), Dr. Deepanjali Patel (RO), Dr Vijay Agarwal (MO) |
|
| Chairperson: Dr. Kumaraswamy (RO), Dr. Sridhar PS (RO) | |||
| 15:40 - 16:00 | Invited (20 Mins) |
Invited Talk: Topic: Proton Therapy for Head Neck Cancer: Evidence & Experience. Dr. Sapna Nagia (RO) |
|
| 16:00 - 16:20 | Invited (20 Mins) |
Invited Talk: Topic: AI in Radiation Oncology Dr. Balakrishna Nair (RO) |
|
| 16:20 - 16:50 | RO (07 Mins) |
2011 |
Stereotactic radiation versus hippocampal avoidance whole
brain radiation in patients with 5-20 brain metastases: A
multicenter, phase 3 randomized trial
Dr. Gayathri Patil (RO) |
| RO (07 Mins) |
5511 |
Priamry Results of a phase 2 study of cisplatin sensitized radiation therapy
Dr. Taher Manaquibwala (RO) |
|
| RO (07 Mins) |
TPS4620 |
A randomized phase 2 study of the efficacy and safety of
stereotactic body radiation therapy (SBRT) in patients
with metastatic urothelial carcinoma and oligoprogression on
maintenance therapy with avelumab (VOLGA 2).
Dr. Shreya Koundinya (RO) |
|
| RO (07 Mins) |
LBA12000 |
PRO-ACTIVE: Results of a pragmatic phase IV randomized trial
comparing the effectiveness of prophylactic swallow
intervention for patients receiving radiotherapy for head and
neck cancer
Dr. Adarsh Gajanan Hegde (RO) |
|
| Moderator: Dr. Sourabha Shetty (RO) | |||
| 16:50 - 17:20 | Panel (30 Mins) |
Panel Discussion:
Dr. Milind Shetti (RO), Dr. Mathangi Padmanabhan (RO), Dr. Vikram Maiya (RO), Dr. Vijay Karan Reddy (RO), Dr. Karthik Hrishi (RO), Dr. Janaki MG (RO) Dr. Lohith Reddy (RO), Dr. Srinivas BJ (MO) |
|
| 17:30 - 18:00 | KEYNOTE (30 Mins) |
Keynote Session: Topic: "Cut Less, Cut More": Tailoring Surgery to Response Dr. Anil D'Cruz |
|
| BENE (LEVEL - 4) | ||||
|---|---|---|---|---|
| Time in Hrs | Track Code | Topics and Session Tracks | ||
| 18:00 - 19:00 | ASCO Poster | Award Poster Presentation - Best of ASCO, Bengaluru | ||
| Award Poster Session | Bene | Level 4 | ||||
| 16:15 - 17:15 | Award Poster Session | Jury ,Dr. Suresh Babu (MO), TBD, TBD | ||
| SESSION HIGHLIGHTS | |||
|---|---|---|---|
| Time in Hrs (IST) | Track Code | Topics and Session Tracks | |
| GBR - 1 | |||
| 10:40 AM - 11:40 AM | Scientific Session | Tracks: HPB, CRC, Gastrointestinal, Cancers | |
| 11:45 AM - 01:20 PM | Scientific Session | Track: Lung & Thoracic Cancers | |
| 01:10 PM - 04:20 PM | Scientific Session | Track: Genitourinary Cancer | |
| 04:45 PM - 05:45 PM | Scientific Session | Track: Gynecologic Cancer | |
| GRAND BALL ROOM | ||||
|---|---|---|---|---|
| Time in Hrs (IST) | Track Code | Paper ID | Topic | |
| 9:10 AM - 9:30 AM | Industry (20 Mins) |
Industry Session by Takeda: Topic: ALT Strategies in the Management of ALK+NSCLC with ALUNBRIG Dr Prasad Narayanan (MO) |
||
| Chairperson: Dr. Sai Ram Chintamadaka (RO) | ||||
| 9:30 AM - 10:00 AM | Keynote (30 Mins) |
Keynote Talk:
Key advancements in management of advanced thyroid cancers -updates from ASCO 2025 Dr. Arvind Krishnamurthy (SO) |
||
| 10:00 AM - 10:20 AM | Industry (20 Mins) |
Industry Session by Bard / BD Topic: Revolutionising PICC placement: What lies in the future Dr. Vivek Agarwala (MO) |
||
| 10:20 AM - 10:40 AM | Industry (20 Mins) |
Industry Session by Astra Zeneca Topic: Newer paradigms in the management of Gastric cancers(Matterhorn) Dr. Amit Rauthan (MO) |
||
| Session 06 | Track: HPB, CRC, Gastrointestinal, Cancers | ||||
| Chairperson: Dr. Poonam Patil (MO), Dr. Vijay Agarwal (MO) | ||||
| 10:40 AM - 11:00 AM | GI (05 Mins) |
LBA1 |
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with
stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). Dr. Sanchayana Mandal (MO) |
|
| GI (05 Mins) |
4000 |
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT):
First results of overall survival (OS) from CheckMate 577. Dr. Abhinav Narwariya (MO) |
||
| GI (05 Mins) |
2511 |
Safety and efficacy of immune checkpoint inhibitors in solid
organ transplant recipients: A systematic review and individual
patient data meta-analysis
Dr. Vijay Kumar Sreenivasalu (MO) |
||
| GI (05 Mins) |
LBA3500 |
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF
V600E-mutant metastatic colorectal cancer (BREAKWATER):
progression-free survival and updated overall survival analyses
Dr. Srikant Ravichandran (MO) |
||
| Moderators: Dr. Vamsi Krishna (MO) | Panelists | |||
| 11:00 AM - 11:20 AM | Panel (20 Mins) |
Panel Discussion: HPB, CRC, Gastrointestinal, Cancers Dr. Anitha Ramesh (MO), Dr. Arun Warrier (MO), Dr. Rajeev L K (MO), Dr. Harish Reddy (MO), Dr. Kumar Saurabh (MO) |
||
| 11:20 AM - 11:25 AM | (05 MINS) | TEA BREAK | ||
| 11:25 AM - 11:45 AM | Industry (20 Mins) |
Industry Session by Astra Zeneca: Topic: Transforming Patient Outcomes with Newer Innovative Therapies in 1L Advanced mHCC (STRIDE) Dr. Govind Babu (MO) |
||
| 11:45 AM - 12:05 PM | Industry (20 Mins) |
M12 |
Industry Session by Roche Topic: Management of uHCC - Defining TACE Unsuitability & Initiating Systemic Therapy Dr Krishna Prasad (MO) |
|
| Session 07 | Lung & Thoracic Cancers | ||||
| Chairperson: Dr Ravi Diwakar (MO), Dr MS Beliappa (RO) | ||||
| 12:05 PM - 12:20 PM | Invited (15 Mins) |
Invited Talk: Topic: Liquid Biopsies for monitoring Lung Cancers Dr K Govind Babu (MO) |
||
| 12:20 PM - 12:35 PM | Invited (15 Mins) |
Invited Talk: Dr Krishna Prasad (MO) |
||
| 12:35 PM - 13:00 PM | LUNG (05 Mins) |
8001 |
Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC:
NeoADAURA receptor-mutated (EGFRm) NSCLC: NeoADAURA.
Dr. Sandip Ganguly (MO) |
|
| LUNG (05 Mins) |
LBA8000 |
Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816. Dr. Alok Modi (MO) |
||
| LUNG (05 Mins) |
8006 |
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive stage small
cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Dr. Aditya Mehta (MO) |
||
| LUNG (05 Mins) |
8503 |
Efficacy of zipalertinib in NSCLC patients with EGFR exon 20
insertion mutations who received prior platinum-based
chemotherapy with or without amivantamab Dr. Aadil Hassan (MO) |
||
| LUNG (05 Mins) |
8506 |
Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. Dr. Basawantrao Malipatil (MO) |
||
| Moderators: Dr. Ullas Batra (RGCI) (MO) | Panelists | |||
| 01:00 PM - 01:20 PM | Panel (20 Mins) |
Panel Discussion: Lung & Thoracic Cancers
Dr. Lohith Reddy (RO), Dr. Vaishnavi Joshi (MO), Dr. Mangesh Kamath (MO), Dr. Aditya Dhanawat (MO), Dr. Abhay Kumar SM (MO) |
||
| 01:20 PM - 01:40 PM | Industry (20 Mins) |
Industry Session by MSD:
Topic: Novel Treatment Option in Lung Cancer with Focus on Pembrolizumab
Dr. Vishwanath Sathyanarayanan (MO) |
||
| 1:40 PM - 2:10 PM | (30 MINS) | Lunch Break | ||
| 2:10 PM - 2:30 PM | Industry(20 Mins) |
Industry Session by Astra Zeneca: Topics: Reimagining EGFRm Advanced lung cancer Dr. Sai Vivek (MO) |
||
| 2:30 PM - 2:50 PM | Industry(20 Mins) |
Industry Session by Glenmark: Topics: Tislelizumab in lung malignancies: Changing the course Dr. Amit Rauthan (MO) |
||
| Session 08 | Genitourinary Cancer | ||||
| Chairperson: Dr. Somorat Bhattacharjee (RO), Dr. Veerendra Kumar KV (SO) | ||||
| 2:50 PM - 3:10 PM | Industry (20 Mins) |
Industry Session by MSD: Topics: Shifting Paradigm in Metastatic Renal Cell Carcinoma with Immunotherapy Dr. C N Patil (MO) |
||
| 3:10 PM - 3:40 PM | GU (05 Mins) |
4500 |
Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable
or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. Dr. Abhinav Narwariya (MO) |
|
| GU (05 Mins) |
4505 |
Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. Dr. Abhilash G H (MO) |
||
| GU (05 Mins) |
4517 |
Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC):
Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study. Dr Aditya (MO) TBC |
||
| GU (05 Mins) |
4514 |
Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). Dr. Anup Hegde (MO) |
||
| GU (05 Mins) |
5002 |
Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC)
intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry. Dr. Venkata Koyyala (MO) |
||
| GU (05 Mins) |
4503 |
Circulating tumor DNA (ctDNA) in patients with muscle invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. Dr. Yogesh Shivakumar (Gen) |
||
| Moderators: Dr. Vinayak Makka (MO) | Panelists | |||
| 3:40 PM - 4:00 PM | Panel (20 Mins) |
Panel Discussion: Genitourinary Cancer
Dr. Ravichandran K (SO), Dr. Vijay Karan Reddy (RO), Dr. Anup Hegde (MO), Dr. Naveen Jayaram Anvekar (MO), Dr. Harish Reddy (MO), Dr. Sateesh CT (MO) |
||
| 4:00 PM - 4:20 PM | Industry (20 Mins) |
Industry Session by Astra Zeneca: Topic:Paradigm shift in the management of advanced endometrial cancer Dr. Rohit Raghunath Ranade (GY) |
||
| 4:20 PM - 4:25 PM | (05 MINS) | TEA BREAK | ||
| Session 09 | Gynecologic Cancer | ||||
| Chairperson: Dr. Linu Jacob (MO), Dr. Radheshyam Naik (MO), Dr Haseeb Abdul Gafoor (RO) | ||||
| 4:25 PM - 4:50 PM | GY (06 Mins) |
5510 |
Nimotuzumab combined with chemotherapy in the first-line
treatment for patients with stage IVB, recurrent or persistent
cervical squamous cell carcinoma: A multi-center, randomized,
double-blind, and controlled study. Dr Muhammad Islam (MO) |
|
| GY (06 Mins) |
LBA5500 |
TRUST: Trial of radical upfront surgical therapy in advanced
ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). Dr. Swathi Prakash (MO) |
||
| GY (06 Mins) |
LBA5507 |
ROSELLA: A phase 3 study of relacorilant in combination with
nab-paclitaxel versus nab-paclitaxel monotherapy in patients
with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). Dr Deepa (MO) |
||
| GY (06 Mins) |
5511 |
Primary results of a phase 2 study of cisplatin-sensitized radiation
therapy and pembrolizumab for unresectable vulvar cancer. Dr. Darshana Rane (MO) |
||
| Moderators: Dr. C N Patil (MO) | Panelists | |||
| 04:10 PM - 05:10 PM | Panel (20 Mins) |
Panel Discussion: Gynecologic Cancer
Dr Sunit Lokwani (MO), Dr Kiran Kattimani (MO), Dr Indoo Ambulkar (MO), Dr Sampath Kumar M N (MO), Dr Subramaniam Murali (MO) |
||
| 05:10 PM - 05:30 PM | Awards (20 Mins) |
Award Papers & Poster - Award Distribution Dr. Suresh Babu (MO) |
||
| Award Distribution | Grand Ball Room) | ||||
| 05:45 PM - 06:05 PM | Award Papers & Poster - Award Distribution Award Distribution |
Award Papers & Poster - Award Distribution Dr. Suresh Babu (MO) |
||
| HALL - 4 (JUPITER) | ||||
|---|---|---|---|---|
| 08:30 AM - 05:00 PM | Focus Session 6 | Yoga | ||
| Parallel Tracks | |||
|---|---|---|---|
| Focused Session | Yoga & Cancer Care | |||
| Time in Hrs (IST) | Track Code | Paper ID | Topic |
| Session Lead Dr Amritanshu Ram | |||
| 8:45 AM - 8:50 AM | (05 Mins) |
Topic: Lighting the lamp Faculty: Dr Prasad Narayanan (MO) |
|
| 8:50 AM - 8:55 AM | (05 Mins) |
Topic: Prayer & Invocation Faculty: TBC |
|
| Session Chair Dr BS Ajaikumar (RO) | |||
| 8:55 AM - 9:25 AM | Keynote (30 Mins) |
Keynote Session Topic: How Much Evidence is Enough: Yoga as the Standard of Care in Oncology Faculty: Dr Lorenzo Cohen |
|
| 9:30 AM - 10:00 AM | Keynote (30 Mins) |
Keynote Talk: Key advancements in management of advanced thyroid cancers - updates from ASCO 2025 Faculty: Dr Arvind Krishnamurthy (SO) |
|
| Session Chair Dr Shekhar Patil (MO) | |||
| 10:10 AM - 10:30 AM | Keynote (30 Mins) |
Keynote Session Topic: Evolving role of yoga as a scalable, evidence-based intervention in supportive cancer care Faculty: MS. Leibel Leigh |
|
| Session Chair: Dr R Nagaratna R, Dr Vinoda Kochupillai (MO) | |||
| 10:40 AM - 10:50 AM | Invited (10 Mins) |
Topic: The journey from alternative to integrative medicine Faculty: Dr Nagaratna R |
|
| 10:50 AM - 11:00 AM | Invited (10 Mins) |
Topic: Holistic healing from an oncolgists perspective Faculty: Dr Vinoda Kochupillai |
|
| 11:00 AM 11:30 AM | Invited (30 Mins) |
Topic: Setting up integrative oncology at HCG Faculty: Dr KS Gopinath |
|
| 11:30 AM - 12:00 PM | Invited (30 Mins) |
Topic: How does Yoga as therapy work? Faculty: Dr Raghavendra Rao |
|
| Moderators: Dr Raghavendra Rao | Panelists | ||
| 12:00 PM - 1:00 PM | Panel (60 Mins) |
Panel Discussion: How much Evidence is enough evidence? - Direction for future research in Yoga in Oncology Faculty: Dr KS Gopinath KS, Dr Kritika Murugan, Dr Brindha Sitaram, Dr Zankhana Buch |
|
| 1:00 PM - 1:30 PM | Special (30 Mins) |
Project Launch: HCG: Elitefit remote yoga monitoring launch Faculty: Mr Ani Bhalekar, Dr Amritanshu Ram |
|
| 1:30 PM - 2:00 PM | Network & Lunch | ||
| Session Chair Dr Kumaraswamy | |||
| 2:00 PM - 2:20 PM | Invited (20 Mins) |
Topic: Role of yoga in modulating salivary cortisol rhythm in breast cancer patients undergoing radiation Faculty: Dr Vadiraja HS |
|
| 2:20 PM - 2:40 PM | Invited (20 Mins) |
Topic: Integrating yoga in Cancer Care Faculty: Dr Anjali Joshi |
|
| 2:40 PM - 3:00 PM | Invited (20 Mins) |
Topic: Effect of pranayama and yoganidra on QOL in cervical cancer patients Faculty: Dr Nuzhat Jahan |
|
| 3:00 PM - 3:20 PM | Invited (20 Mins) |
Topic: Living with Cancer is more important than dying of cancer. An integrated approach Faculty: Dr Birendranath Banerjee |
|
| 3:20 PM - 3:40 PM | Invited (20 Mins) |
Topic: Effects of integrated yoga therapy on cognition and cardiac functions in patients with breast carcinoma undergoing chemotherapy Faculty: Dr Inbaraj G |
|
| 3:40 PM - 4:00 PM | Invited (20 Mins) |
Topic: Yoga for Cancer Survivorship Faculty: Dr Praseeda Menon . |
|
| 4:00 PM - 4:20 PM | Invited (20 Mins) |
Topic: Integrating yoga into cancer care. US experience in research and clinical practice Faculty: Dr Smitha Malliah |
|
| Moderators: Dr Amritanshu Ram | Panelists | ||
| 4:20 PM - 4:50 PM | Panel (30 Mins) |
Panel Discussion: How to integrate yoga into Oncology Practice: Experiences, Challenges and opportunities Faculty: Dr Vadiraja HS, Dr Smitha Malliah, Dr Yamuna Badiger, Dr Amruth Kadam (RO), Dr Shivaram Verambally |
|
| HALL - 5 (NEPTUNE) | ||||
|---|---|---|---|---|
| 09:00 AM - 05:00 PM | Focus Session 7 | Research Methodolgy | ||
| Focused Session | Research Methods| Hall 5 | ||||
| Session Lead Dr Gururaj Arakeri | ||||
| Time in Hrs (IST) | Topic | Speaker | ||
| 09:00 AM - 09:15 AM | Inaugural program | |||
| 09:15 AM - 09:45 AM | What is Health Research? Why Research? | Dr. Nagesh Lakshminarayan | ||
| 09:45 AM - 10:15 AM | Procedural steps in Health Research | Dr. Nagesh Lakshminarayan | ||
| 10:15 AM - 10:45 AM | Framing a research Question- PO, PEO and PICO Format | Dr. Shyam Sivasamy | ||
| 10:45 AM - 11:00 AM | Tea Break | |||
| 11:00 AM - 11:45 AM | Hypothesis Testing | Dr. Nagesh Lakshminarayan | ||
| 11:45 AM - 12:30 PM | Research Designs - Overview | Dr. Shyam Sivasamy | ||
| 12:30 PM - 01:15 PM | Errors in Health Research and Error minimization methods | Dr. Nagesh L | ||
| 01:15 PM - 01:45 PM | Lunch Break | |||
| 01:45 PM - 02:30 PM | Fundamentals of Biostatistics (Data, Scales of measurements and implications) | Dr. Shyam Sivasamy | ||
| 02:30 PM - 03:30 PM | Measures of central tendency, Measures of Dispersion and Tests of Significance | Dr. Shyam Sivasamy | ||
| 03:30 PM - 04:30 PM | Scientific Writing – An Overview | Dr. Nagesh Lakshminarayan | ||
| 04:30 PM - 04:50 PM | Q and As | |||
| 04:50 PM - 05:00 PM | Valedictory | |||
| HALL - 6 (PLUTO) | |||
|---|---|---|---|
| Session Highlights | |||
| Time in Hrs | Track Code | Topics and Session Tracks | |
| 10:00 AM - 12:00 PM | Focus Session 8 | Nuclear Oncology | |
| 02:00 PM - 05:00 PM | Scientific Session | Track: Pediatric Hematology Oncology | |
| Session 10 | Pediatric Oncology | ||||
|---|---|---|---|---|
| Chairperson: Dr. Appaji L, Dr. Raghuram P | ||||
| 01:30 PM - 02:00 PM | INVITED (30 MINS) |
Invited Talk: Topic: Recent advances in the Management of Neuroblastoma Dr. Girish Chinnaswi |
||
| 2:00 PM - 3:00 PM | PO (07 MINS) |
1000 |
Association of immunotherapy of high-risk neuroblastoma patients with long term infusion of dinutuximab beta with
survival over short term infusion: Results from the HR-NBL1/SIOPEN trial. Dr. Pooja Prakash Mallya |
|
| PO (07 MINS) |
10001 |
A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report. Dr. Ravi Joshi |
||
| PO (07 MINS) |
10005 |
Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma. Dr. Shashank Bhojaraja |
||
| PO (07 MINS) |
10009 |
Promoting Resilience in Stress Management (PRISM): A randomized controlled trial of a psychosocial intervention for adolescents and young adults with advanced cancer. Dr. Rhea Daruvala |
||
| PO (07 MINS) |
10013 |
CCDI-COG molecular characterization initiative: The expanding data on childhood cancer. Dr. Gautam Balram |
||
| PO (07 MINS) |
10014 |
Genomic newborn screening for cancer risk: A retrospective cohort study. Dr. Somdipa Pal |
||
| PO (07 MINS) |
10016 |
Cognitive outcomes following proton vs. photon radiotherapy for CNS nongerminomatous germ cell tumors: A Children’s Oncology Group study Dr. Aarthi N |
||
| PO (07 MINS) |
10019 |
Second malignant neoplasm risk after mediastinal radiotherapy for pediatric Hodgkin lymphoma on Children’s Oncology Group AHOD1331. Dr. Amit Galgali |
||
| 3:00 PM - 3:20 PM | Industry (20 MINS) |
Industry Session by BMS: Topic: RCC Topic - Improving Survival and Quality of Life in frontline advanced RCC with CTLA-4 & PD-1 inhibition : 8-year update. Dr. Rajeev Vijayakumar (MO) |
||
| Moderators: Dr. Intezar Mehdi | Panelists | |||
| 3:20 PM - 3:50 PM | PANEL (30 MINS) |
Panel Discussion: Pediatric Oncology Dr. Shobha, Dr. Rasmi Thallessery, Dr. Srinivas Chillikuri, Dr. Smitha, Dr. Anand KC, Dr. Brindha Sitaram, Dr. Mithua Ghosh, Dr. Vinay MV |
||
| Focused Session | Nuclear Oncology | ||||
| Time in Hrs | Speaker | Session Title | ||
| 10:00 AM - 10:30 AM | Dr. Harish Babu | Basics & Applications of Nuclear Medicine in a Nutshell | ||
| 10:30 AM - 11:00 AM | Dr. Shiva Kumar Swamy | What You Have to Know About FDG PET/CT ? | ||
| 11:00 AM - 11:20 AM | Tea Break | |||
| 11:20 AM - 11:50 AM | Dr. Mahesh A | Nuclear Medicine Imaging in Neuroendocrine Tumours (NET) | ||
| 11:50 AM - 12:20 PM | Dr. Kiran Kumar JK | Ga 68 PSMA and Other Radiotracers | ||
| 12:20 PM - 12:50 PM | Dr. Murthy S | Nuclear Medicine Therapy – Current Practices | ||
| Session Highlights HALL - 7 | ||||
|---|---|---|---|---|
| 10:00 AM - 01:30 PM | Focus Track | Surgical Oncology | ||
| Session 10 | Track: Surgical Oncology Focus Track | ||||
| Chairperson: Dr. Ravi Arjunan (SO), Dr Narendra H (SO), Dr. Nanda Rajneesh (SO) | ||||
| Time in Hrs | Track Code | Topics and Session Tracks | ||
| 10:15 AM - 10:45 AM | INVITED (30 MINS) |
Invited Talk: Journey of a surgical oncologist - past, present and future Dr. Raj Nagarakar (SO) |
||
| Chairperson: Dr. Deepak Rautray (SO), Dr. Shishir Shetty (SO) | ||||
| Moderator: Dr. Jagannath Dixit (SO) | ||||
| 10:45 AM - 11:30 AM | Panel (45 MINS) |
Panel Discussion: AI in Robotic surgery Dr. Mohan Krishnamurthy (SO), Dr. Jayanti Thumsi (SO,) Dr. Lohit Reddy (RO), Dr. Pawan Sugoor (SO), Dr. Narasimhaiah Sreenivasiah (SO), Dr. Sudhakar (Rad), Dr. Yash Mathur (SO), Dr. Srinivas Gopinath (SO) |
||
| Chairperson: Dr. Mahesh Bandemagal (SO), Dr. Deepak Khanna (SO), Dr. Shivpal Saini (SO) | ||||
| 11:30 AM - 12:00 PM | Invited (30 MINS) |
Invited Talk: Bridging the gap between the technology and the sergeon Mr. Devareddy (HealthTech) |
||
| Chairperson: Dr Sqn Ldr Swati Batra (SO), Dr Ashwin KR (SO), Dr Jyoti Ranjan Swain (SO) | ||||
| 12:00 PM - 12:25 PM | GY (05 MINS) |
5583 |
Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advancedstage or recurrent ovarian cancer:
A systematic review and meta-analysis of randomized controlled trials. Dr Vishnu Kurpad (SO) |
|
| GY (05 MINS) |
LBA5501 |
Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial. Dr Renu Sharma (SO) |
||
| GY (05 MINS) |
4008 |
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus
immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the
phase III AIO/CALGP/ACO-GAIN-Trial. Dr Aditya Kalaskar (SO) |
||
| GY (05 MINS) |
3505 |
Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized
phase 3 trial (CAIRO6). Dr Kapil Dev (SO) |
||
| GY (05 MINS) |
4007 |
Primary results of a phase 2 study of cisplatin-sensitized radiation
therapy and pembrolizumab for unresectable vulvar cancer Dr Aakarsh G Kini (SO) |
||
| Chairperson: Dr. Rohan Shetty (SO), Dr. Prabhu Nesargikar (SO), Dr Ravi Chander Veligeti (SO) | ||||
| Moderator: Dr Suraj Manjunath (SO) | ||||
| 12:20 PM - 1:05 PM | PANEL (40 MINS) |
Panel Discussion: ASCO Update: What can we imbibe into India practice Dr Sharanbasappa Hatti (SO), Dr Rudresh Tabali (SO), Dr Tanay Shah (SO), Dr Rohini Kulkarni (SO), Dr Palaniappan Ramanathan (SO), Dr Karthik Raichurkar (SO), Dr Hemanth GN (SO), Dr Vijaykumar M (SO) |
||
| 1:05 PM - 1:35 PM | Network (30 MINS) | LUNCH BREAK | ||
Copyright© 2025 Designed & Developed by GHA Conferences